Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications
Author:
Publisher
Elsevier BV
Subject
General Medicine,Surgery
Reference32 articles.
1. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial;Baselga;Lancet,2012
2. Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer;Buzdar;Ann Oncol,2009
3. Clinical and translational results of CALGB 40601: a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer;Carey;J Clin Oncol,2013
4. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis;Cortazar;Lancet,2014
5. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial;Gianni;Lancet Oncol,2012
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype;Scientific Reports;2023-08-08
2. Imaging of HER2 detected receptor expression positive breast cancer: from detection to interpretation;Egyptian Journal of Radiology and Nuclear Medicine;2023-07-14
3. Involvement in Tumorigenesis and Clinical Significance of CXCL1 in Reproductive Cancers: Breast Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer and Prostate Cancer;International Journal of Molecular Sciences;2023-04-14
4. Discovery of Pyrimidine- and Coumarin-Linked Hybrid Molecules as Inducers of JNK Phosphorylation through ROS Generation in Breast Cancer Cells;Molecules;2023-04-13
5. Fatty acid synthase: a druggable driver of breast cancer brain metastasis;Expert Opinion on Therapeutic Targets;2022-05-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3